Author

Marika Porrazzo

Observed name: M. Porrazzo

Observed institutions: University of Trieste, Policlinico Umberto I, Ospedale Maggiore, Ospedale Vincenzo Cervello, Azienda sanitaria universitaria Giuliano Isontina, Sapienza University of Rome

ORCID: 0000-0001-6487-5971

Observed ORCID: 0000-0001-6487-5971

OpenAlex ID: A5031992080

Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL)

2020 · Francesca Romana Mauro, Diana Giannarelli, et al. · Leukemia · 81

PDF

Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs

2021 · Candida Vitale, Chiara Salvetti, et al. · Blood · 45

PDF

Digital droplet PCR at the time of TKI discontinuation in chronic‐phase chronic myeloid leukemia patients is predictive of treatment‐free remission outcome

2019 · Gioia Colafigli, Emilia Scalzulli, et al. · Hematological Oncology · 23

Prognostic Significance of PET/CT in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline Chemoimmunotherapy

2020 · Marika Porrazzo, Emanuele Nicolai, et al. · Cancers · 12

PDF

Clinical relevance of silent red blood cell autoantibodies

2017 · Francesca R. Mauro, Fabio Trastulli, et al. · Haematologica · 12

PDF

Richter transformation in diffuse large B-cell lymphoma in patients with chronic lymphocytic leukemia receiving ibrutinib: risk factors and outcomes

2025 · Sara Pepe, Candida Vitale, et al. · Leukemia · 11

PDF

Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients

2024 · Danilo De Novellis, Daniele Derudas, et al. · European Journal Of Haematology · 9

PDF

Light-chain cardiac amyloidosis: a case report of extraordinary sustained pathological response to cyclophosphamide, bortezomib, and dexamethasone combined therapy

2022 · Aldostefano Porcari, Linda Pagura, et al. · European Heart Journal - Case Reports · 7

PDF

Repeated successful use of eltrombopag in chronic primary immune thrombocytopenia: description of an intriguing case

2017 · Cristina Santoro, Paola Volpicelli, et al. · Clinical Case Reports · 6

PDF

A real-life study of daratumumab-bortezomib-dexamethasone (D-VD) in lenalidomide exposed/refractory multiple myeloma patients: a report from the Triveneto Myeloma Working Group

2023 · Gregorio Barilà, Francesca Maria Quaglia, et al. · Annals of Hematology · 5

PDF

A real‐world retrospective–prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience

2024 · Anna Furlan, Michele Cea, et al. · Cancer Medicine · 4

PDF

Serological and cellular response to mRNA-SARS-CoV2 vaccine in patients with hematological lymphoid malignancies: Results of the study “Cervax”

2023 · Sara Mohamed, Elisa Lucchini, et al. · Frontiers in Oncology · 3

PDF

The role of an accurate diagnosis of inherited thrombocytopenia as the basis for an effective treatment. A case of MYH9 syndrome treated with a TPO‐RA

2019 · Marika Porrazzo, Erminia Baldacci, et al. · Haemophilia · 3

Impact of daratumumab/bortezomib/thalidomide and dexamethasone induction therapy on chemo-free stem cell mobilization in transplant-eligible newly diagnosed multiple myeloma: a multicenter real-world experience

2024 · Marika Porrazzo, Tiziana Moscato, et al. · Haematologica · 2

PDF

Single centre experience on Acquired Haemophilia A patients: Diagnosis, clinical management and analysis of factors predictive of response and outcome

2021 · Marika Porrazzo, Erminia Baldacci, et al. · Haemophilia · 2

PDF

Regional Standardization of CLL Management: Results of a Delphi Consensus Process

2026 · Enrica Antonia Martino, Annalisa Chiarenza, et al. · European Journal Of Haematology · 1

Optimizing Fixed‐Duration Ven‐I Regimen in CLL: Expert Insight and AI Comparison

2026 · V. Innao, A. Figuera, et al. · Hematological Oncology · 1

Lenalidomide maintenance after bortezomib, thalidomide and dexamethasone (VTD) induction and autologous stem cell transplantation: an Italian real-life study of 602 patients

2025 · Gregorio Barilà, Angela Grassi, et al. · Haematologica · 1

PDF

Chronic Lymphocytic Leukemia (CLL) Patients Quality of Life (QoL): A Cross-Sectional Analysis of the Italian Experience in the Choice Study during the First Wave of the COVID-19 Pandemic

2021 · Alessandra Tedeschi, Idanna Innocenti, et al. · Blood · 1

PDF

Severe COVID-19 Infection in Patients with Chronic Lymphocytic Leukemia or Indolent B-Cell Non-Hodgkin Lymphoma Who Received Pre-Exposure Prophylaxis with Tixagevimab and Cilgavimab in Italy: Preliminary Results of the Observational Study By the Gimema Working Party on Chronic Lymphoproliferative Disorders and By the Fondazione Italiana Linfomi

2024 · Gian Matteo Rigolin, Antonio Urso, et al. · Blood

PDF

P-360 Impact of Daratumumab/Bortezomib/Thalidomide/Dexamethasone (DVTD) Induction Therapy on Chemo-Free Stem Cell Mobilization in Newly Diagnosed Multiple Myeloma Patients: A Real Life Experience

2024 · Marika Porrazzo, Tiziana Moscato, et al. · Clinical Lymphoma Myeloma & Leukemia

Lenalidomide Maintenance after VTD Induction and Autologous Stem Cell Transplantation: An Italian Real-Life Study of 558 Patients

2023 · Gregorio Barila, Angela Grassi, et al. · Blood

PDF

P970: a Real-world Retrospective-prospective Analysis of Efficacy and Safety of Combined Ixazomib, Lenalidomide and Dexamethasone in Relapsed/refractory Multiple Myeloma: the Northern Italy Experience

2023 · Anna Furlan, Michele Cea, et al. · HemaSphere

P49 a Real-world Retrospective-prospective Analysis of Efficacy and Safety of Combined Ixazomib, Lenalidomide and Dexamethasone in Relapsed/refractory Multiple Myeloma: the Northern Italy Experience

2023 · A. Furlan, M. Cea, et al. · HemaSphere

P20 Lenalidomide Maintenance After Vtd Induction and Autologous Stem Cell Transplantation: Preliminary Results of a Real-life Study Including 389 Patients

2023 · G. Barilà, A. Pascarella, et al. · HemaSphere

Works count: 29

Citation count: 229

H-index: 7

I10-index: 6